Envoy Medical Appoints Experienced Medical Device Executive Charles McKhann to Board
COCH sits 97% above its 52-week low of $0.363 on light trading volume (0.1× avg).
Summary
Envoy Medical, Inc. has appointed Charles S. McKhann, a seasoned medical device executive with a track record of leadership in acquired companies, to its Board of Directors.
Key Events · Executive and Board Changes · COCH
-
New Director Appointed
Charles S. McKhann, an experienced medical device executive, was appointed as a Class I director to the Board of Directors, effective April 15, 2026.
-
Board Expansion and Committee Role
The Board of Directors expanded from six to seven members, and Mr. McKhann was also appointed to the Compensation Committee.
-
Experienced Industry Leader
Mr. McKhann brings a strong background, including prior CEO roles at Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific Corporation.
-
Stock Option Grant
He was awarded stock options to purchase 100,000 shares of Class A Common Stock at an exercise price of $0.72 per share, vesting over 36 months.
Analysis · COCH · Industrial Applications And Services
The addition of Mr. McKhann, who previously served as CEO of two medical device companies acquired by Boston Scientific, brings significant industry expertise and strategic leadership to Envoy Medical's board. His experience in scaling and exiting companies could be invaluable for the company's future direction. The board also expanded from six to seven members to accommodate this appointment, and Mr. McKhann will join the Compensation Committee. He was granted 100,000 stock options at an exercise price slightly above the current market price, aligning his incentives with long-term shareholder value.
At the time of this filing, COCH was trading at $0.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $55M. The 52-week trading range was $0.36 to $1.91. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.